SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an upcoming earnings report against the backdrop of potential U.S. cannabis rescheduling and regulatory shifts. The community remains deeply divided, with some betting on a turnaround fueled by medical growth and policy changes, while others express frustration over leadership, dilution, and long-term performance.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently experiencing significant market volatility driven by a disappointing first-quarter delivery report that missed analyst expectations, fueling intense community debate regarding the company's core automotive demand versus its long-term AI and robotics narrative. While some investors view the stock's weakness as a prime opportunity to buy the dip, others are aggressively betting against the position, citing concerns over declining sales, global competition, and the potential distraction of the anticipated SpaceX IPO.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is trending due to significant insider and institutional accumulation coupled with an exceptionally low float, fueling community speculation about a potential short squeeze. Investors are closely monitoring upcoming earnings and company conference calls as potential catalysts to ignite further momentum.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is experiencing significant volatility and elevated trading volume as investors aggressively speculate on potential buyout scenarios and M&A activity following unconfirmed media reports. The community is actively debating the company's valuation as a standalone rare-disease franchise versus its appeal as an acquisition target, with many traders closely watching abnormal after-hours trading patterns for signals of a catalyst.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space is currently trending as investors speculate on potential contract opportunities and the sector-wide tailwinds expected from an anticipated SpaceX IPO. While retail sentiment remains highly divided between bullish expectations for a short squeeze on the company's small float and bearish skepticism regarding the firm's lack of revenue and recent leadership turnover.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as investors weigh aggressive geopolitical escalations in the Middle East and spiking oil prices against persistent market resilience. The community is actively debating whether current price action is a government-led stabilization effort, a classic bull trap, or a sign that the market is beginning to price in further macro instability.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a positive trial update for its prostate cancer candidate, rinzimetostat, combined with a $125 million private placement financing. While some investors are expressing disappointment over the dose optimization results, the community is heavily debating the stock's future potential, with many pointing to its clean safety profile, strong cash position, and heavy institutional backing as signs of a potential long-term recovery.

Vine Hill Capital Investment Corp. is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on May 24, 2024 and is headquartered in Fort Lauderdale, FL.

CoinShares Plc.

CoinShares is capturing attention following its Nasdaq listing, with the community analyzing the firm's valuation gap compared to U.S. competitors and debating the impact of post-SPAC volatility. Investors are currently weighing the company's profitability and dividend potential against broader crypto market sentiment and geopolitical pressures affecting the sector.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it joins the S&P 500 index, triggering mandatory buying from index funds and ETFs alongside continued speculative interest linked to AI infrastructure investments. The community is sharply divided, with bulls pointing to the company's critical role in the photonics supply chain and recent hyperscaler backing, while bears argue the valuation has reached unsustainable levels and is primed for a significant correction.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense community scrutiny following a major exploit on the Drift Protocol, fueling debates about network security and institutional trust. While some investors are accumulating on dips based on developer momentum, others are concerned about market volatility and the long-term impact of regulatory pressures on the broader ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tatva Chintan has broken out of a 1.5-year downtrend, both technically and fundamentally, suggesting the start of a new growth cycle, according to SEBI-registered analyst&nbsp;<a href="https://stocktwits.com/Rajneesh_Sharma_Official">Rajneesh Sharma</a>.<stembedurl>https://stocktwits.com/Rajneesh_Sharma_Official/message/617166023</stembedurl>At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TATVA.NSE">Tatva Chintan shares</a> were trading at ₹939.65, up ₹6.9 or 0.7% on the day.He highlights the upcoming EURO 7 emission standards as a structural growth driver, with light-duty vehicles affected from July 2025 and heavy-duty from July 2027.&nbsp;This will increase catalyst requirements by 2.8 times per vehicle. Tatva is estimated to capture $15–22 million of the incremental Solvent Deasphalting Agent (SDA) total addressable market, with the ramp starting in the third quarter (Q3).Sharma also points to the company’s global-first alternate synthesis route for an agrochemical molecule as a new high-margin growth pillar, with bulk orders secured and commercial shipments planned for Q3.&nbsp;The management expects combined agrochemical and SDA growth of 40–70% in FY26. Additional growth levers include electrolyte salts, which are expected to grow 2–3 times from the first quarter (Q1), and four pharma intermediates currently in validation or commercial supply.On guidance, Sharma said FY26 revenue is expected to grow over 25% year-on-year, with core profit margins expanding from 9% to 20%.&nbsp;He identified key milestones, including electrolyte salts and initial SDA volumes in Q1, followed by full SDA and agrochemical molecule ramp in Q3.From a technical perspective, Sharma confirms that the long-term downtrend channel since late 2022 has been decisively broken, with the ₹825–850 resistance level now acting as strong support.&nbsp;He noted a bullish RSI divergence, with the relative strength index (RSI) at 62.63, indicating momentum without overbought conditions.&nbsp;The breakout occurred on volume of about 2 million shares, versus an average of 25,500, suggesting institutional accumulation.On valuation, Sharma notes FY25 revenue was flat and profit-after-tax sharply lower, but FY26 is poised for sharp revenue and margin expansion, making Tatva a re-rating candidate.&nbsp;He identified risks, including the pace of the adoption of EURO 7, the commissioning of the PASC plant, and commodity volatility affecting SDA margins.Sharma said that Tatva Chintan could be entering a new cycle driven by EURO 7 and the agrochemical molecule. It has strong support at ₹825–850 and medium-term price targets of ₹1,250–₹1,300 over 12 to 18 months.&nbsp;He advised investors to watch SDA volumes in Q3, agrochemical molecule scaling, and margin improvement toward 20% core profit.On Stocktwits, retail sentiment was ‘bullish’ amid ‘normal’ message volume.The stock has risen 9.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tatva Chintan Enters New Growth Cycle With EURO 7, Agro Push: SEBI RA Rajneesh Sharma

The analyst sees potential for a sharp FY26 turnaround and a medium-term re-rating.

Equity

Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The firm is engaged in the manufacture of portfolio, which includes structure directing agents(SDAs), phase transfer catalysts(PTCs), electrolyte salts for super capacitor batteries, and pharmaceutical and agrochemical intermediates and other specialty chemicals(PASC). The company was founded on June 12, 1996 and is headquartered in Vadodara, India.

TATVA.NSE
Tatva Chintan Pharma Chem Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest TATVA.NSE News

TATVA.NSETatva Chintan Pharma Chem Ltd.